CervoMed Inc. - Common Stock CRVO 深 滬
等待開盤 08-07 09:30:00 美东时间
9.69
-0.360
-3.58%
華盛通- 最 高9.97
- 今 開9.79
- 成交量 20.61万股
- 最 低 9.56
- 昨 收 10.05
- 總市值 8432.92万
- 52周最高 20.63
- 市盈率 靜 --
- 換手率 2.37%
- 52周最低 1.80
- 委 比 -23.90%
- 總股本 870.27万
- 歷史最高 17437.50
- 量 比 0.71
- 振 幅 4.08%
- 歷史最低 1.80
- 每 手 1
- 風險率 4.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CervoMed Shares Business and Financial Updates Online
CervoMed ( ($CRVO) ) has issued an announcement. CervoMed Inc. has made availab...
08-06 04:50
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
CervoMed Inc. (NASDAQ: CRVO) announced that its management will participate in a fireside chat and investor meetings at the CG 45th Annual Growth Conference in Boston from August 12 to 14, 2025. The fireside chat will take place on August 12 at 2:00 PM ET and can be accessed via a webcast link on the CervoMed website. The company, focused on developing treatments for age-related neurologic disorders, is currently evaluating neflamapimod, an inves...
08-05 12:00
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good tolerability.
07-28 23:20
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
CervoMed Inc. announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial, showing that oral neflamapimod reduced the risk of clinically significant worsening by 54% (p=0.0037) and 64% (p=0.0001) in patients with minimal evidence of AD co-pathology. This decrease was observed in patients with ptau181 < 2.2 pg/mL. Additionally, neflamapimod demonstrated a significant reduction in plasma levels of GFAP, a biomarker of n...
07-28 11:00
D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $10 price target.
07-25 19:11
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
CervoMed Inc.将举行电话会议和网络直播，分享关于痴呆症药物neflamapimod的IIb期RewinD-LB研究最新结果，包括32周扩展阶段的首要终点。会议将于2025年7月28日8:00 AM ET举行，并紧随2025阿尔茨海默病协会国际会议精神。
07-24 20:05
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
Boston, July 8, 2025 - CervoMed Inc. (NASDAQ: CRVO) announced it will present results from the Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB) at the Alzheimer’s Association International Congress 2025 in Toronto. The presentations will include new findings and will be available both virtually and in-person. For more details, visit the Investor section of CervoMed’s website. Neflamapimod is an investigational drug tar...
07-08 11:00
CervoMed Stockholders Approve Key Proposals at Annual Meeting
CervoMed ( ($CRVO) ) has shared an update. On June 23, 2025, CervoMed Inc. held...
06-26 05:29
百奥泰：眼科抗VEGF单抗III期研究成功，即将申报上市
（转自：药研网） 6月24日，百奥泰宣布抗VEGF人源化单抗BAT5906针对新生血管性年龄相关性黄斑变性（w-AMD）的关键注册III期临床研究成功达到预设的...
06-24 17:59
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
CervoMed has appointed Marco Verwijs, PhD, as Executive Vice President of Technical Operations to oversee its CMC division and advance the development of neflamapimod through Phase 3 testing. Dr. Verwijs, with extensive experience in drug development, will help prepare for commercial manufacturing and a Phase 3 trial in dementia with Lewy Bodies (DLB) set to begin mid-2026. The company also granted him stock options as part of his employment indu...
06-10 12:00
